GlobalData on MSN1d
Sanofi reports Q4 2024 increase in net income to $916mSanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...
Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...
Q4 guidance included expanded metrics for 2025, such as mid to high single-digit sales growth and low double-digit EPS growth, compared to a more cautious outlook in Q3. Management also introduced a ...
Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...
Reports Business EPS of EUR 1.31, down 11.0% at CER and down 14.9% reported. Reports Q4 IRFS net sales EUR 10.56B, up 9.1% reported and up ...
BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Deutsche Bank upgraded Sanofi (SNY) to Hold from Sell with a price target of EUR 100, up from EUR 85, following the company’s “solid” Q4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback